Raising Expectations
Building best-in-class therapeutics to reduce the burden of neurodegenerative diseases because patients and caregivers deserve better.
Overcoming Barriers
Delivering safe, efficacious drugs to the central nervous system (CNS) remains one of the greatest challenges in medicine. This is driven by the blood-brain barrier (BBB), which restricts the entry of large molecules into the CNS, preventing many potential therapeutics from reaching their intended targets.
In partnership with Paragon Therapeutics, Korsana has developed Therapeutic Targeting (THETA™), a novel BBB-penetrant shuttle platform designed to enhance CNS exposure of investigational therapies and overcome limitations of earlier shuttle technologies.
Using THETA, Korsana is advancing precision-engineered therapeutics designed to reduce the burden of some of medicine’s biggest challenges, starting with Alzheimer’s disease.
Learn more about the burden and difficulties of treating Alzheimer’s disease, and our potential best-in-class therapeutic approach.
Latest News
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer
Proven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry
Korsana Biosciences to Present at the Stifel 2026 Virtual CNS Forum
WALTHAM, Mass.–Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Jonathan Violin, Ph.D., President…